Allergic rhinitis (AR) affects 7.8% of U.S. adults and 10‐30% of the population worldwide. AR symptoms (rhinorrhea, congestion, sneezing, nasal/ocular pruritus, and postnasal drainage) significantly impact sleep and reduce cognitive and emotional functioning affecting work and
school productivity. Although effective, intranasal corticoid (INS) steroid delivery systems are often associated with adverse sensory attributes, affecting patient adherence and reducing efficacy. Patient satisfaction with treatment characteristics predicts adherence levels that can better
inform treatment decisions. This study was designed to evaluate psychometric evidence for the self-administered Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale as a patient-reported outcomes measure for use in clinical research. Analytic methods included qualitative analysis
of patient focus groups and psychometric analysis of scale data collected from 185 AR subjects enrolled in a randomized, 2-week, crossover, comparative U.S. clinical trial. Qualitative analysis conceptually supported nine treatment satisfaction subscales. Reliability by Cronbach alpha met
accepted standards. Evidence was found for construct validity using structural equation modeling, criterion validity from correlation patterns between treatment satisfaction and health-related quality of life scales, and discriminant validity analysis based on AR symptom-defined groups. Responsiveness
was shown by significant change in treatment satisfaction subscales among AR symptom change groups. Scores on treatment preference items discriminated between the aqueous and aerosol INS formulations. The ARTSP scale is a conceptually sound, reliable, valid, and responsive measure of patient
evaluations of alternative therapies, providing detailed information about treatment characteristics that are likely to influence adherence levels and subsequent AR clinical control.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
intranasal corticoid steroids;
patient reported outcomes;
Document Type: Research Article
Phase V Technologies, Inc., Wellesley Hills, Massachusetts, USA
Publication date: November 1, 2013
More about this publication?
Allergy and Asthma Proceedings
is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP
welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC)
, AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science
and Science Citation Index Expanded
, plus the National Library of Medicine's PubMed
- Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Ingenta Connect is not responsible for the content or availability of external websites